Merck vet Michael Rosenblatt joins R&D exodus to the startup world
Merck Chief Medical Officer Michael Rosenblatt recently caused quite a stir when he suggested that a lot of academic research work in the drug field is a mess, urging that investigators be forced to return at least some of their funding if industry scientists can’t reproduce their work.
And now, Rosenblatt will get to explain his position on a face-to-face basis.
Cambridge, MA-based Flagship Ventures, which has been soaking up academic research in its quest to start up a string of new biotechs, has named Rosenblatt as its very first CMO. And he’s been tapped to play a leading role in spawning a new wave of upstarts at Flagship.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
